Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.330
Neutral
RSI(14)
31.673
Neutral
STOCH(KDJ)(9,3,3)
16.518
Sell
ATR(14)
0.106
Low Volatility
CCI(14)
-107.178
Sell
Williams %R
80.027
Oversold
TRIX(12,20)
-2.235
Sell
StochRSI(14)
0.000
Sell
Search
Lipocine Inc
LPCNAdd to Watchlist
2.260USD
-0.070-3.00%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
13.92MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Lipocine Inc
Currency: USD Updated: 2026-05-15Key Insights
Lipocine Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 148 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 6.00.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Lipocine Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Lipocine Inc Highlights
StrengthsRisks
Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics. The Company’s clinical development candidates include: LPCN 1154, oral brexanolone, for the treatment of postpartum depression, LPCN 2101, for the treatment of epilepsy, LPCN 2203, an oral candidate targeted for the management of essential tremor, LPCN 2401, an oral proprietary anabolic androgen receptor agonist for improved body composition in obesity management, and LPCN 1148, for the management of decompensated cirrhosis. It is also developing LPCN 1107, for the prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, and LPCN 1144, for the treatment of metabolic dysfunction-associated steatohepatitis. Its product candidate, TLANDO, is a novel oral prodrug of testosterone containing testosterone undecanoate developed by the Company.
Growing
The company is in a growing phase, with the latest annual income totaling USD 1.98M.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Overvalued
The company’s latest PE is -1.15, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 2.08M shares, increasing 42.40% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 37.40K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 1.03.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
6.000
Target Price
+157.51%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-15The current financial score of Lipocine Inc is 6.48, ranking 235 out of 382 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 119.40K, representing a year-over-year increase of 27.20%, while its net profit experienced a year-over-year increase of 96.90%.
Score
Financials
8.12
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.59
Operational Efficiency
2.84
Growth Potential
6.78
Shareholder Returns
7.08
Lipocine Inc's Company Valuation
Currency: USD Updated: 2026-05-15The current valuation score of Lipocine Inc is 7.33, ranking 128 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.15, which is -293975.17% below the recent high of 3391.03 and -859.40% above the recent low of -11.07.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 148/382
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-15The current earnings forecast score of Lipocine Inc is 7.00, ranking 312 out of 382 in the Biotechnology & Medical Research industry. The average price target is 6.88, with a high of 7.00 and a low of 6.75.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
6.000
Target Price
+165.49%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
554
Total
5
Median
6
Average
Company name
Ratings
Analysts
Lipocine Inc
LPCN
2
CRISPR Therapeutics AG
CRSP
29
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Beigene Ltd
ONC
26
Ionis Pharmaceuticals Inc
IONS
25
1
2
3
...
111
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-15The current price momentum score of Lipocine Inc is 6.19, ranking 275 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 2.44 and the support level at 2.14, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
2.312
Sell
MA10
2.337
Sell
MA20
2.342
Sell
MA50
4.368
Sell
MA100
6.520
Sell
MA200
4.772
Sell
Institutional Confidence
Currency: USD Updated: 2026-05-15The current institutional shareholding score of Lipocine Inc is 3.00, ranking 193 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 25.27%, representing a quarter-over-quarter increase of 35.40%. The largest institutional shareholder is James Simons, holding a total of 38.50K shares, representing 0.47% of shares outstanding, with 33.39% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-05-15The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Lipocine Inc is 2.66, ranking 203 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 0.49. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
0.48
VaR
+6.62%
240-Day Maximum Drawdown
+82.77%
240-Day Volatility
+178.51%
Return
Best Daily Return
60 days
+15.77%
120 days
+22.22%
5 years
+32.27%
Worst Daily Return
60 days
-77.84%
120 days
-77.84%
5 years
-77.84%
Sharpe Ratio
60 days
-1.48
120 days
+0.82
5 years
-0.05
Risk Assessment
Maximum Drawdown
240 days
+82.77%
3 years
+82.77%
5 years
+93.83%
Return-to-Drawdown Ratio
240 days
-0.38
3 years
-0.22
5 years
-0.19
Skewness
240 days
-5.57
3 years
-3.20
5 years
-2.27
Volatility
Realised Volatility
240 days
+178.51%
5 years
+118.67%
Standardised True Range
240 days
+17.75%
5 years
+26.75%
Downside Risk-Adjusted Return
120 days
+71.80%
240 days
+71.80%
Maximum Daily Upside Volatility
60 days
+177.01%
Maximum Daily Downside Volatility
60 days
+164.69%
Liquidity
Average Turnover Rate
60 days
+7.67%
120 days
+4.98%
5 years
--
Turnover Deviation
20 days
+88.71%
60 days
+329.60%
120 days
+179.07%
Peer Comparison
Biotechnology & Medical Research
Lipocine Inc
LPCN
5.92 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.48 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Exelixis Inc
EXEL
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
